Join NowSummary
Sign in / Join NowSummaryA slew of undisclosed or thinly disclosed executive team departures in the diagnostics division, which represents over 82.8% of revenue, could signal business decline and a compliance "house cleaning".The quiet departure of key employees in the company's renal division underscore issues with the rollout of Opko's FDA approved drug, Rayaldee.The company is employing "co pay assist" programs in the roll out of Rayaldee in an apparent attempt to compete with low cost generic over the counter alternatives.Pipeline delays and disclosure oddities give us doubt about the value of remaining pipeline assets.A low cash balance coupled with negative free cash flow and regulatory overhang could signal a near term liquidity crunch.Introduction Opko has dropped approximately 25% since its recent quarterly report issued last Wednesday after it missed estimates on both revenue and earnings. In addition to the continued disappointing sales in the com...